ReDream Brands Launches as the Leading Direct-to-Consumer Platform for Sleep Apnea and Sleep Health

Rhea-AI Summary

ReDream Brands, backed by Cathay Capital, has launched as a new direct-to-consumer sleep health platform focused on cash-pay obstructive sleep apnea (OSA) customers across North America, uniting four established brands: cpap.com, The CPAP Shop, Lofta, and sleeping.com.

The launch follows a joint venture between cpap.com and AdaptHealth (NASDAQ: AHCO) that combined cpap.com, sleeping.com, and The CPAP Shop, plus the subsequent acquisition of Lofta. Supported by a new credit facility led by Twin Brook Capital Partners, the integrated platform ships over 700,000 customer orders annually from three U.S. warehouses and aims to expand digital engagement, diagnostics, education, and long-term customer support.

Positive

• Platform combines four leading DTC sleep brands under one umbrella
• Over 700,000 customer orders shipped annually across three U.S. warehouses
• Backed by Cathay Capital with new credit facility led by Twin Brook Capital Partners
• Joint venture with AdaptHealth (NASDAQ: AHCO) plus acquisition of Lofta completed

Negative

• None.

Market Context

Recent insider activity recorded 83,500 shares bought and 22,550 shares sold across the reviewed per...

Analysis

Recent insider activity recorded 83,500 shares bought and 22,550 shares sold across the reviewed period. This ownership context complemented the platform launch, while the risk data classified short positioning as low.

Key Figures

Brands combined: four brands Americans with OSA: 40 million Americans Undiagnosed adults: 80% +5 more

8 metrics

Brands combined four brands ReDream Brands launch

Americans with OSA 40 million Americans Estimated U.S. obstructive sleep apnea population

Undiagnosed adults 80% Estimated share of adults with OSA remaining undiagnosed and untreated

Diagnosed market $8 billion Estimated diagnosed sleep apnea market

Annual orders over 700,000 customer orders annually Combined ReDream Brands operations

Warehouses three warehouses East, Central, and Western U.S.

Assets managed over €6B (~$7B) Cathay Capital

Investments made over 320 investments Cathay Capital since 2007

Historical Context

5 past events · Latest: Aug 07 (Neutral)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Aug 07	Investor conferences	Neutral	-8.3%	Conference participation announcement was followed by an 8.26% 24-hour decline.
Aug 04	Q2 earnings report	Negative	-38.0%	Goodwill impairment and lowered guidance accompanied a 38.04% 24-hour decline.
Jul 20	Business acquisition	Positive	+2.1%	Cardinal Health announced two acquisitions, followed by a 2.09% 24-hour gain.
Jul 20	Diabetes divestiture	Positive	+2.1%	AdaptHealth announced a $235 million divestiture, followed by a 2.09% gain.
Jul 14	Earnings date notice	Neutral	+3.9%	Second-quarter earnings scheduling notice preceded a 3.93% 24-hour gain.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Historical reactions were mixed: the August 4 earnings report and August 7 conference notice preceded declines, while the July 20 divestiture and July 14 earnings-date notice preceded gains.

Key Terms

obstructive sleep apnea, osa, cpap, home sleep testing

4 terms

obstructive sleep apnea medical

"serve the cash-pay obstructive sleep apnea (OSA) market across North America"

Obstructive sleep apnea is a common medical condition where the throat repeatedly narrows or closes during sleep, causing short pauses in breathing, drops in blood oxygen and fragmented rest. It matters to investors because it creates ongoing demand for medical devices, diagnostics, treatments and sleep-monitoring services, and it can affect population health, workforce productivity and healthcare spending—like a recurring leak in a system that requires continual repair and monitoring.

osa medical

"obstructive sleep apnea (OSA) market across North America"

Obstructive sleep apnea (OSA) is a common sleep disorder where the upper airway repeatedly narrows or collapses during sleep, causing brief breathing stoppages that fragment rest and raise daytime tiredness and health risks. For investors, OSA creates sustained demand for diagnostic tests, therapy devices, drugs and monitoring services, so changes in clinical data, approvals, or reimbursement can materially affect revenue prospects for companies in the sleep-health sector.

cpap medical

"cpap.com as the largest full-service retailer for the direct-pay OSA market"

A CPAP (continuous positive airway pressure) device is a machine that gently blows a steady stream of air through a mask to keep a person’s breathing passages open during sleep, commonly used to treat sleep apnea. For investors, CPAPs matter because they represent a medical-device market with recurring sales of equipment and disposable supplies, subject to safety reviews, insurance reimbursement rules and regulatory approvals that can affect a maker’s revenue and reputation.

home sleep testing medical

"Lofta as the industry leader in home sleep testing and coaching"

Home sleep testing is a diagnostic method using small, portable devices that patients wear overnight at home to record breathing, oxygen levels, heart rate and movement to detect sleep-disordered breathing such as sleep apnea. For investors, it matters because it shifts testing out of sleep labs into consumer or clinic settings, affecting demand for devices, data platforms, remote monitoring services and reimbursement — like moving a lab test into your living room, which can expand market size and change cost structures.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

New platform brings four of the industry's most recognized direct-to-consumer brands together to serve the cash-pay obstructive sleep apnea (OSA) market across North America

NEW YORK, Aug. 17, 2026 /PRNewswire/ -- Cathay Capital today announced the launch of ReDream Brands, a new consumer sleep health platform dedicated to helping millions of people achieve better sleep and healthier lives. The platform brings together four of the industry's most recognized direct-to-consumer brands: cpap.com, The CPAP Shop, Lofta and sleeping.com, creating a leading platform for cash-pay OSA customers across North America.

The launch follows a series of strategic transactions executed by Cathay Capital-backed cpap.com, including the formation of a joint venture with AdaptHealth (NASDAQ: AHCO) bringing together cpap.com, sleeping.com, and The CPAP Shop, along with the subsequent acquisition of Lofta. The four brands now comprise the ReDream Brands platform. The transactions were supported by a new credit facility led by Twin Brook Capital Partners.

Obstructive sleep apnea remains one of the most widespread yet underdiagnosed chronic conditions in the U.S. An estimated 40 million Americans are believed to be suffering from OSA, yet an estimated 80% of such adults remain undiagnosed and untreated. The diagnosed sleep apnea market alone is estimated at $8 billion, which reflects only a fraction of the category's full opportunity, given how many OSA sufferers have yet to be identified and treated.

One Platform, Distinct Brands

Each brand will continue to operate under its own name and serve its own customer base: cpap.com as the largest full-service retailer for the direct-pay OSA market; The CPAP Shop as the market leader in value and convenience; Lofta as the industry leader in home sleep testing and coaching as customers begin their recovery journey; and sleeping.com as a private-label provider of CPAP supplies and sleep-related products sold across the ReDream Brands platform and beyond.

Behind these distinct consumer brands, the ReDream Brands platform will operate as a single, integrated business designed to bring greater scale, reach, and capability to a category that has been underserved by traditional channels. Combined, the brands ship over 700,000 customer orders annually from three warehouses across the East, Central, and Western U.S.

Elevating the Consumer Sleep Journey

"Millions of people struggle with health-impacting sleep disorders that too often go undiagnosed or untreated," said Joe Megibow, Chief Executive Officer of ReDream Brands. "ReDream Brands was created to change that. By bringing together the best brands, talent, and capabilities in our industry, we're building a platform that makes it dramatically easier for consumers to understand their sleep health, access effective treatment, and improve their quality of life. We are excited to combine the power of these brands to serve their customers better than they could on their own."

The ReDream Brands platform will continue to invest in each of its brands while expanding shared capabilities across digital engagement, diagnostics, education, and long-term customer support. The platform creates meaningful benefits for customers, including:

• Expanded reach to the large and largely undiagnosed population of OSA sufferers across North America
• Expanded clinical education and sleep health resources
• Enhanced digital shopping experiences across brands
• Faster national fulfillment and enhanced customer support
• Continued investment in innovation to support the customer sleep journey
• Greater product selection from both leading and emerging manufacturers.

"This is an exciting and transformative milestone in launching ReDream Brands, and an important step in serving the tens of millions of people suffering from OSA by focusing on sleep health at scale," said Mark Woods, Partner at Cathay Capital. "Joe and the management team have built an exceptional business centered on serving the customer. Bringing together four premier brands creates a platform with the scale, talent, and resources to lead the next chapter of consumer sleep health."

The platform is positioned for continued organic growth and further strategic expansion as sleep health becomes a growing focus within preventive healthcare.

About ReDream Brands

ReDream Brands is a new platform building the leading consumer offering dedicated to improving sleep health. Through its family of trusted brands - including cpap.com, The CPAP Shop, Lofta, and sleeping.com, - the platform provides consumers across North America with comprehensive solutions for the diagnosis and treatment of obstructive sleep apnea and other sleep-related conditions, including CPAP equipment, masks, home sleep testing, accessories, educational resources, and personalized customer support. ReDream Brands is backed by Cathay Capital. For more information, visit: redream.co.

About Cathay Capital

Cathay Capital is a global private equity and venture capital investment firm supporting healthcare, technology and consumer companies throughout North America, Europe, and Asia. The firm helps middle-market companies and startups navigate opportunities for growth, international expansion, and sustainable transformation. Its platform connects people with global reach and local expertise – from investors and entrepreneurs to management teams and leading corporations – to share knowledge, the tools to scale and transform businesses.

Founded in 2007 with a strong entrepreneurial heritage, Cathay Capital now manages over €6B (~$7B) in assets. It has made over 320 investments from offices in New York, San Francisco, Paris, Munich, Berlin, Madrid, Mexico City, Shanghai, Beijing, and Singapore. For more information, visit: www.cathaycapital.com.

Media Contact

press@redream.co

View original content to download multimedia:https://www.prnewswire.com/news-releases/redream-brands-launches-as-the-leading-direct-to-consumer-platform-for-sleep-apnea-and-sleep-health-302852461.html

SOURCE Cathay Capital

FAQ

What is ReDream Brands and how does it relate to AdaptHealth (NASDAQ: AHCO)?

ReDream Brands is a direct-to-consumer sleep health platform uniting four OSA-focused brands. According to Cathay Capital, its launch follows a joint venture between cpap.com and AdaptHealth (NASDAQ: AHCO) that combined cpap.com, sleeping.com, and The CPAP Shop into a shared platform.

Which brands are included in the new ReDream Brands sleep apnea platform launched in August 2026?

ReDream Brands includes cpap.com, The CPAP Shop, Lofta, and sleeping.com. According to ReDream Brands, each brand keeps its own identity and customer base while operating on a single integrated business platform focused on obstructive sleep apnea diagnosis, treatment products, and support.

How large is the ReDream Brands direct-to-consumer sleep apnea business in terms of orders?

ReDream Brands reports shipping over 700,000 customer orders annually across its platform. According to the company, these orders are fulfilled from three warehouses in the Eastern, Central, and Western United States, supporting nationwide reach for cash-pay obstructive sleep apnea customers.

What market need is ReDream Brands targeting in obstructive sleep apnea (OSA)?

ReDream Brands targets the large, underdiagnosed OSA population in the United States. According to Cathay Capital, an estimated 40 million Americans may have OSA, with about 80% undiagnosed, and the diagnosed sleep apnea market alone is estimated at roughly $8 billion in value.

How will ReDream Brands improve the consumer sleep journey for OSA patients?

ReDream Brands plans to invest in digital engagement, diagnostics, education, and long-term support. According to the company, customers should benefit from expanded clinical education, improved digital shopping experiences, faster national fulfillment, broader product selection, and continued innovation across its four integrated brands.

Who backs ReDream Brands financially and what role does the new credit facility play?

ReDream Brands is backed by investment firm Cathay Capital. According to Cathay Capital, recent strategic transactions forming the platform, including the joint venture and Lofta acquisition, were supported by a new credit facility led by Twin Brook Capital Partners to fund growth and integration.